NanoPass
NanoPass Technologies Ltd. is a pioneer in the development and commercialization of nearly painless intradermal delivery solutions for vaccines and drugs. Its flagship product, the 0.6mm MicronJet600 microneedle, is the first and only true (<1mm) microneedle to receive FDA clearance as an intradermal delivery device for substances approved for delivery below the surface of the skin. It has proven its efficacy in vaccination delivery with improved potency, immunogenicity and dose sparing. Supported by extensive clinical data and regulatory approvals in leading markets, NanoPass is ready to expand its reach by partnering with pharma companies aiming to provide better patient care worldwide. The company supports multiple phase I-III clinical studies and is actively pursuing additional partnerships with vaccine developers worldwide. NanoPass Technologies Ltd. was founded in 2000 by Dr. Shuki Yeshurun, a material scientist and an expert in micro system technology (MEMS).
Go To Site

INVESTING PARTNER/FUND:

Join Our Mailing ListSign up to receive regular updates from our blog and news about Viola